Morgan Stanley raised the firm’s price target on Haleon to $10.95 from $9.90 and keeps an Overweight rating on the shares. The firm also removed the shares as a Top Pick. As one of the best-performing stocks in European staples year-to-date, Haleon offers less absolute upside from here, the analyst tells investors in a research note. However, the firm continue to favors the company relative to other food alternatives.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HLN:
- Haleon launches Eroxon gel for erectile dysfunction
- Haleon PLC Sponsored ADR (HLN) Unveils Dividend Details for Q3: Mark Your Calendar!
- Haleon U.S. shares initiated with a Buy at Berenberg
- Haleon downgraded to Neutral from Buy at Goldman Sachs
- Haleon price target raised to 385 GBp from 370 GBp at Morgan Stanley